unistrain prrs süstesuspensiooni lüofilisaat ja lahusti
laboratorios hipra s.a. - sigade reproduktiiv-respiratoorse sündroomi viirus - süstesuspensiooni lüofilisaat ja lahusti - 125annus 10tk; 100annus 10tk
ingelvac prrsflex eu süstesuspensiooni lüofilisaat ja lahusti
boehringer ingelheim vetmedica gmbh - sigade reproduktiiv-respiratoorse sündroomi viirus - süstesuspensiooni lüofilisaat ja lahusti - 1ml 1annus 10annus 12tk; 1ml 1annus 50annus 1tk; 1ml 1annus 100annus 12tk; 1ml 1annus 250annus 25tk; 1ml 1annus 250annus 12tk; 1ml 1annus 10annus 1tk; 1ml 1annus 100annus 25tk; 1ml 1annus 10annus 25tk; 1ml 1annus 50annus 25tk; 1ml 1annus 250annus 1tk
valocordin diazepam suukaudsed tilgad, lahus
krewel meuselbach gmbh - diasepaam - suukaudsed tilgad, lahus - 10mg 1ml 25ml 1tk
multibic potassium-free hemodialüüsi-/hemofiltratsioonilahus
fresenius medical care deutschland gmbh - naatriumkloriid+kaltsiumkloriiddihüdraat+magneesiumkloriid+glükoos+naatriumvesinikkarbonaat - hemodialüüsi-/hemofiltratsioonilahus - 6,048g+0,2205g+0,1016g+1,1g+3,066g 1l 5000ml 2tk
duosol ilma kaaliumita hemofiltratsioonilahus
b. braun avitum ag - naatriumkloriid+kaltsiumkloriiddihüdraat+magneesiumkloriid+glükoos+naatriumvesinikkarbonaat - hemofiltratsioonilahus - 4,21g+1,98g+0,91g+9,9g+0/6,18g+0+0+0+3,59g 1000ml 555ml 2tk / 4445ml 2tk
vistaprep suukaudse lahuse pulber
tillotts pharma ab - makrogool+naatriumkloriid+naatriumvesinikkarbonaat+kaaliumkloriid - suukaudse lahuse pulber - 105g+2,8g+1,43g+0,37g 4tk
aservo equihaler
boehringer ingelheim vetmedica gmbh - ciclesonide - hingamiselundite muud ravimid hingamisteede obstruktiivsete haiguste, inhalants - hobused - eest leevendamine kliinilised tunnused on raske hobuste astma (varem tuntud korduvad hingamisteede obstruktsioon – (rao), suvel karjamaal seotud korduvate hingamisteede obstruktsioon – (spa-rao)).
persovac süstesuspensiooni lüofilisaat ja lahusti
ceva-phylaxia zrt. - sigade reproduktiiv-respiratoorse sündroomi viirus - süstesuspensiooni lüofilisaat ja lahusti - 100annus 1tk; 50annus 1tk
imatinib koanaa
koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - respiratoorsed süntsüütilised viirusinfektsioonid - vaktsiinid - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.